Pharmaceuticals (Apr 2024)

Functionalization of <sup>68</sup>Ga-Radiolabeled Nanodiamonds with Octreotide Does Not Improve Tumor-Targeting Capabilities

  • Thomas Wanek,
  • Marco Raabe,
  • Md Noor A Alam,
  • Thomas Filip,
  • Johann Stanek,
  • Mathilde Loebsch,
  • Christian Laube,
  • Severin Mairinger,
  • Tanja Weil,
  • Claudia Kuntner

DOI
https://doi.org/10.3390/ph17040514
Journal volume & issue
Vol. 17, no. 4
p. 514

Abstract

Read online

Nanodiamonds (NDs) are emerging as a novel nanoparticle class with growing interest in medical applications. The surface coating of NDs can be modified by attaching binding ligands or imaging probes, turning them into multi-modal targeting agents. In this investigation, we assessed the targeting efficacy of octreotide-functionalized 68Ga-radiolabelled NDs for cancer imaging and compared it with the tumor uptake using [68Ga]Ga-DOTA-TOC. In vivo studies in mice bearing AR42J tumors demonstrated the highest accumulation of the radiolabeled functionalized NDs in the liver and spleen, with relatively low tumor uptake compared to [68Ga]Ga-DOTA-TOC. Our findings suggest that, within the scope of this study, functionalization did not enhance the tumor-targeting capabilities of NDs.

Keywords